Jane Street
ARTV

Jane Street’s Artiva Biotherapeutics ARTV Stock Holding History

Jane Street’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254K Sell
39,496
-1,175
-3% -$5.81K ﹤0.01% 9589
2025
Q4 		$174K Buy
+40,671
New +$154K ﹤0.01% 9838
2025
Q3 		– Sell
-44,215
Closed -$66.8K – 12029
2025
Q2 		$66.8K Buy
+44,215
New +$92.9K ﹤0.01% 9102

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Jane Street's ARTV Position: Q1 2026 in Review

Jane Street reduced its Artiva Biotherapeutics (ARTV) stake by 2.9% in Q1 2026, selling an estimated $5.81K and leaving 39,496 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #9589.

Jane Street first reported a position in ARTV in Q2 2025 and has held it in 3 quarters since. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Jane Street held 39,496 shares of Artiva Biotherapeutics worth $254K as of Q1 2026.
  • Jane Street sold 1,175 Artiva Biotherapeutics shares in Q1 2026, an estimated $5.81K.
  • Artiva Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #9589 holding.
  • Jane Street first reported a position in Artiva Biotherapeutics in Q2 2025 and has held it in 3 quarters since.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.